🇺🇸 SECQuantum Biopharma Ltd.Codex · 实盘不做把握 9/10不做原因:无增量信息🔁 +1 同一事件
北京时间·🕒 发布 00:38:45·⟳ 抓取 00:39:02 +17s·⚡ 决策 09-09 00:43:52 +4m50s·49.2 天前
Quantum BioPharma 6-K/A 仅补录旧的 Allucent MS 试验 LOI 新闻稿
这份 6-K/A 只是把 2026-03-30 的旧 LOI 新闻稿并入注册声明，明确没有其他变更；没有新的合同、审批、融资或临床推进事实可改变方向、标的或执行价，因此不构成新的交易催化。
📄 原文Quantum Biopharma Ltd.↗ 原文
----- qntm6ka090826.htm ----- 6-K/A 1 qntm6ka090826.htm FORM 6-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Was…
不做 Quantum BioPharma Ltd.（QNTM.US）
仅为旧 LOI 的技术性 6-K/A 补录，没有新增可交易事实。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
事件本身是行政性归档，不是新增业务事实。原始 3 月 30 日 LOI 已经公开，9 月 8 日的 6-K/A 只是在 F-3 中引用该附件，没有新的定价边际；因此应回避而不是据此交易。
消息传播链
- 原始新闻稿披露与 Allucent 签署 binding LOI，计划推进 Lucid-MS 的 Phase 2 多发性硬化试验。市场反应:无本轮新增可观察反应；这一步对应的是 3 月份旧消息。
- 本次 6-K/A 明确表示仅把 Exhibit 99.1 并入 F-3，除该说明外不修改原始报告。市场反应:无新增定价边际。
关键理由
- 9 月 8 日披露没有新增商业或监管进展，只是技术性修订。
- 可交易信息仍停留在 3 月 30 日的旧 LOI，边际已过。
- 没有新的金额、条款、审批或临床结果，缺乏正期望。
主要风险
- 若后续出现正式试验启动、IND 进展或合作条款落地，才会重新形成可交易催化。
- 小盘生物科技对单一临床消息敏感，但本次文件本身不提供新边际。
反向证据
- 做多前查反向 · 来源 web · 日期 2026-05-07 · 影响 weakens
后续公开披露已在 5 月财报中提到 IND application filed，说明 3 月 LOI 后续已进入常规推进；本次 6-K/A 不提供新边际。
检索:Quantum BioPharma 2026-09-08 6-K/A 是否有新增临床/融资/监管进展 原文 ↗
先例如何影响了这次决策
对本次决策的影响:先例未改变结论；直接回避。
方向:无可用高相似交易先例，且本事件不是实质催化。
涨幅量级:不适用；这是技术性补录，不是可类比的商业/监管事件。
形态:不适用。
工具执行结果 · 成功 4 · 降级 0 · 失败 0 · 取消 0
- web_search 成功 ? · 0 ms
- web_search 成功 ? · 0 ms
- web_search 成功 ? · 0 ms
- web_search 成功 ? · 0 ms
原文全文
展开原文 · 2,008 字
----- qntm6ka090826.htm -----
6-K/A
1
qntm6ka090826.htm
FORM 6-K/A
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K/A
REPORT OF FOREIGN
PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE
ACT OF 1934
For the month of September
2026
Commission File Number: 001-39152
QUANTUM
BIOPHARMA LTD.
(Registrant)
1 Adelaide Street
East, Suite 801
Toronto, Ontario M5C
2V9
(Address of Principal
Executive Offices)
Indicate by check mark whether the Registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
EXPLANATORY NOTE
This Amendment No. 1
(this “
Amendment No. 1
”) to the report on Form 6-K originally furnished with the U.S. Securities and Exchange Commission
on March 30, 2026, Accession Number 0001171843-26-002008 (the “
Initial Report
”), is being furnished solely to incorporate
Exhibit 99.1 filed as part of the Initial Report into the Registrant’s Registration Statement on
Form F-3
(File No. 333-276264). Except
as set forth herein, there are no other changes to the Initial Report.
1
DOCUMENTS INCORPORATED
BY REFERENCE
Exhibit 99.1 included
with this Amendment No. 1 is hereby incorporated by reference into the Registrant’s Registration Statement on
Form F-3
(File No. 333-276264)
and shall be deemed to be a part thereof from the date on which the Initial Report was furnished, to the extent not superseded by documents
or reports subsequently filed or furnished.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
QUANTUM BIOPHARMA LTD.
(Registrant)
Date: September 8, 2026
By
/s/ Donal Carroll
Donal Carroll
Chief Financial Officer
3
EXHIBIT INDEX
Exhibit
Description of Exhibit
99.1
Press Release dated March 30, 2026 (incorporated by reference to Exhibit 99.1 to the Form 6-K furnished on March 30, 2026, Accession No. 0001171843-26-002008)
4
6-K/A
1
qntm6ka090826.htm
FORM 6-K/A
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K/A
REPORT OF FOREIGN
PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE
ACT OF 1934
For the month of September
2026
Commission File Number: 001-39152
QUANTUM
BIOPHARMA LTD.
(Registrant)
1 Adelaide Street
East, Suite 801
Toronto, Ontario M5C
2V9
(Address of Principal
Executive Offices)
Indicate by check mark whether the Registrant
files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
EXPLANATORY NOTE
This Amendment No. 1
(this “
Amendment No. 1
”) to the report on Form 6-K originally furnished with the U.S. Securities and Exchange Commission
on March 30, 2026, Accession Number 0001171843-26-002008 (the “
Initial Report
”), is being furnished solely to incorporate
Exhibit 99.1 filed as part of the Initial Report into the Registrant’s Registration Statement on
Form F-3
(File No. 333-276264). Except
as set forth herein, there are no other changes to the Initial Report.
1
DOCUMENTS INCORPORATED
BY REFERENCE
Exhibit 99.1 included
with this Amendment No. 1 is hereby incorporated by reference into the Registrant’s Registration Statement on
Form F-3
(File No. 333-276264)
and shall be deemed to be a part thereof from the date on which the Initial Report was furnished, to the extent not superseded by documents
or reports subsequently filed or furnished.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
QUANTUM BIOPHARMA LTD.
(Registrant)
Date: September 8, 2026
By
/s/ Donal Carroll
Donal Carroll
Chief Financial Officer
3
EXHIBIT INDEX
Exhibit
Description of Exhibit
99.1
Press Release dated March 30, 2026 (incorporated by reference to Exhibit 99.1 to the Form 6-K furnished on March 30, 2026, Accession No. 0001171843-26-002008)
4
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。